300639 凯普生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.074-3.333-14.6002.87642.609
总资产报酬率 ROA (%)-0.067-2.986-12.6562.25431.460
投入资产回报率 ROIC (%)-0.071-3.202-14.1322.76440.125

边际利润分析
销售毛利率 (%)43.65845.46547.67561.02969.364
营业利润率 (%)-2.742-23.357-100.7593.85739.185
息税前利润/营业总收入 (%)-20.129-30.955-102.0182.29137.968
净利润/营业总收入 (%)-5.108-27.221-116.5326.20332.193

收益指标分析
经营活动净收益/利润总额(%)700.81962.06822.93517.449130.114
价值变动净收益/利润总额(%)0.549-2.273-1.10537.8701.003
营业外收支净额/利润总额(%)5.9467.6281.350-15.710-3.069

偿债能力分析
流动比率 (X)5.3005.3765.0416.2553.229
速动比率 (X)5.0905.2004.8926.0593.142
资产负债率 (%)11.93011.71412.46910.95122.454
带息债务/全部投入资本 (%)2.1822.3172.0570.7292.261
股东权益/带息债务 (%)4,376.0304,148.5034,668.23113,367.9604,194.715
股东权益/负债合计 (%)755.439771.496712.904775.256324.196
利息保障倍数 (X)1.1695.460-845.860-2.198-755.637

营运能力分析
应收账款周转天数 (天)486.410481.514658.279751.262123.204
存货周转天数 (天)84.20662.85469.69391.29127.911